Previous close | 62.00 |
Open | 62.00 |
Bid | 66.70 |
Ask | 70.60 |
Strike | 150.00 |
Expiry date | 2024-05-17 |
Day's range | 62.00 - 62.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.